TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00003549
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003549
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01698723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04007367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217 matching placebo capsule
Study: NCT02171442
Drug: BIBR 953 ZW Intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg, 2.8 MBq (76 µCi)
Study: NCT01756196
Drug: Spinal Steroid Injection
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid Injection
Study: NCT03621657
Drug: Low Dose FMT Capsule DE
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.
Study: NCT03621657
Drug: Single Dose FMT Capsule DE
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.
Study: NCT03621657
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.
Study: NCT00862524
Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, escalating
Study: NCT01815450
Drug: BLI1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI1100 topical cream
Study: NCT01815450
Drug: BLI1100 - modified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI1100 topical cream
Study: NCT01815450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical cream
Study: NCT02551055
Drug: MLN1117
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN1117 Tablets
Study: NCT01522326
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400mg tablet. Take one dose by mouth.
Study: NCT00430300
Drug: UK-432,097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
Study: NCT00430300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing 100% lactose administered BID using an atomizer device
Study: NCT01899768
Drug: GSK2339345
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
Study: NCT01899768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
Study: NCT02204059
Drug: hMAb BIWA 4
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01941563
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01042925
Drug: XL147 (SAR245408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once daily as tablet(s)
Study: NCT01633788
Drug: AGN-195263 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of AGN-195263 0.1% instilled in each eye twice daily.
Study: NCT01633788
Drug: AGN-195263 0.03%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of AGN-195263 0.03% instilled in each eye twice daily.
Study: NCT01633788
Drug: AGN-195263 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of AGN-195263 0.01% instilled in each eye twice daily.
Study: NCT00092664
Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01633788
Drug: AGN-195263 Vehicle
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
Study: NCT01849055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01849055
Drug: LY3023703
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01849055
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03930927
Drug: remineralizing agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: enamel regeneration
Study: NCT03531710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT04012541
Drug: post-myocardial infarction management
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin, clopidogrel, ticagrelor
Study: NCT00865202
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
Study: NCT01459445
Drug: Metformin, Ethinylestradiol 30µg-Drospirenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
Study: NCT03295396
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
Study: NCT01694823
Drug: CS-ACI
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:~Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）
Study: NCT00623766
Drug: Corticosteroid: Methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
Study: NCT02082665
Drug: Rosuvastatin10 mg tablet
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
Study: NCT02707224
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT03813199
Drug: ABX464 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 is a new anti-inflammatory drug
Study: NCT03813199
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching with ABX464
Study: NCT03813199
Drug: ABX464 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 is a new anti-inflammatory drug
Study: NCT03813199
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
Study: NCT01511640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 2x daily for duration of study
Study: NCT03297944
Drug: Placebo (PLC/PLC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at night, placebo administered in the morning.
Study: NCT01703923
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02695381
Drug: Etodolac-lidocaine topical patch
Normalized name: lidocaine Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT02695381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT03547791
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of normal saline 3ml twice 24hours apart
Study: NCT04510649
Drug: Part B
Normalized name: Hem-Care Premium 7-Part Blend Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16
Study: NCT00394407
Drug: sliding scale regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI acqhs
Study: NCT00394407
Drug: glargine basal insulin and glulisine prandial insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: glargine insulin once a day and glulisine insulin three times a day as long as patient eating
Study: NCT02999906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sugar pill) for three times daily oral administration
Study: NCT00623766
Drug: Corticosteroid: Prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
Study: NCT00020917
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00020917
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03278444
Drug: Arginine hydrochloride
Normalized name: Arginine Hydrochloride
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
Study: NCT01084473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 % NaCl will be infused.
Study: NCT00515944
Drug: Botulinum neurotoxin type A, free of complexing proteins
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04476108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00312728
Drug: First-Line Chemotherapy Agents
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline.
Study: NCT00312728
Drug: Second-Line Chemotherapy Agents
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline.
Study: NCT03570957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution for injection in vial
Study: NCT02555449
Drug: [¹⁴C]-LY3202626
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as solution by mouth
Study: NCT03573999
Drug: NaCl 7.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml/kg will be administered before dura opening
Study: NCT01118377
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine was supplied as film-coated tablets.
Study: NCT00268918
Drug: PTK787
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants may continue receiving study drug as long as their disease does not worsen
Study: NCT03181464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline .9% injection
Study: NCT02348125
Drug: Mitochondrial Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00575523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
Study: NCT01462058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily, 12 weeks
Study: NCT01771978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received 250 ml of a 5% dextrose solution as placebo
Study: NCT04039126
Drug: CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pleurodesis is the obliteration of the pleural cavity by inducing adhesions of the visceral and parietal pleural layers, mostly used in patients with pleural effusions, pneumothorax (18). The use of pleurodesis to induce pleural symphysis between the pleural layers dates backs to the beginning of the 20th century by Benthune(19) and has continued to evolve with different Thoracic surgeons and researchers still looking for the ideal pleurodesis agent.
Study: NCT00502671
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250mg/m2 po bid on days 1-14 of each 3 week cycle
Study: NCT01179581
Drug: GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Description: single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
Study: NCT01179581
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, oral solution or capsule (matching corresponding study medication)
Study: NCT01179581
Drug: GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, capsule, 10 days
Study: NCT01179581
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, capsule, 10 days
Study: NCT03633344
Drug: Carbowhite
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03633344
Drug: Carbowhite placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03071068
Drug: Anti-PlGF recombinant monoclonal antibody, 4mg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intravitreal injections of THR-317 4mg approximately 1 month apart
Study: NCT03071068
Drug: Anti-PlGF recombinant monoclonal antibody, 8mg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intravitreal injections of THR-317 8mg approximately 1 month apart
Study: NCT00092014
Drug: Risendronate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Study: NCT01919944
Drug: VLY-686
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules containing either 10 mg or 50 mg VLY-686
Study: NCT01919944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
Study: NCT02042521
Drug: Dietary Supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.
Study: NCT02042521
Drug: Lactose Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
Study: NCT00669214
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Study: NCT00092014
Drug: Alendronate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Study: NCT02327728
Drug: Botulinum toxin A 12.5U
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00717951
Drug: docetaxol, cisplatin, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
Study: NCT04441112
Drug: Ketorolac Intraarticular Injection
Normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injections will be given under ultrasound guidance with one of two possible medications.
Study: NCT01227980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
Study: NCT03903081
Drug: HEC110114 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once daily
Study: NCT03903081
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114
Study: NCT01573598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo given orally, once per day
Study: NCT02398240
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days: 1 and 15 Dose: 25 mg/m2/dose.
Study: NCT04275193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granule manufactured to mimic Zishenqing(containing 10% composition)
Study: NCT00486759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study: NCT02174328
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid once a day until 36 week
Study: NCT02174328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once a day until 36 week
Study: NCT02868151
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
Study: NCT02868151
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
Study: NCT02631148
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg controlled release melatonin tablet
Study: NCT02631148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet identical to circadin
Study: NCT03647657
Drug: Sacuitril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N
Study: NCT00997919
Drug: MABT5102A
Approvals — FDA: no, EMA: no, PMDA: no
Description: single SC dose
Study: NCT00997919
Drug: MABT5102A
Approvals — FDA: no, EMA: no, PMDA: no
Description: single IV dose
Study: NCT02926989
Drug: Plasmalyte Glucos 50 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
Study: NCT02926989
Drug: 0.45% saline in 5% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
Study: NCT00726648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules for 4 weeks
Study: NCT01613677
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01372969
Drug: Cx601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
Study: NCT02405156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04486651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as IV infusion on Day 1 of each 21-day cycle.
Study: NCT02635607
Drug: rhCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
Study: NCT03564652
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single prophylaxis dose of 20 mg/kg in suspension form, reconstituted by trial staff before dose administration by the same.
Study: NCT01134562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV injection.
Study: NCT01060137
Drug: fentanyl matrix
Normalized name: FentaNYL Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl transdermal patch 12 - 25mcg/hr
Study: NCT02525796
Drug: eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eplerenone, titrated up to a maximum of 50mg BID
Study: NCT02525796
Drug: amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amiloride, titrated up to a maximum of 10mg BID
Study: NCT03656094
Drug: Placebo plus chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy
Study: NCT02338245
Drug: ASLAN001
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASLAN001 400mg BID
Study: NCT02338245
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
Study: NCT01745367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no